e3 (S1207) Breast Cancer Study

S1207

S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer -- e3 Breast Cancer Study (Evaluating Everolimus with Endocrine Therapy)

Physician and Research Staff Educational Materials

The materials in this section are designed for the use of health care professionals and have not been reviewed and approved for use as patient education materials.

  • e3 (S1207) Presentation Poster (PDF):  The attached poster was used to introduce the e3 (S1207) study at the December 2012 San Antonio Breast Cancer Symposium.
  • e3 (S1207) Protocol Abstract Page (members only):  Includes links to the full trial protocol and related materials. Physicians and research staff from non-SWOG sites can find these by logging on to the CTSU site.

e3 Media Relations

Patient Educational Materials

The National Cancer Institute Central Institutional Review Board (CIRB) has reviewed and approved the educational materials below. Please get approval from your local IRB, if needed, before distributing these materials to your patients.

  • * e3 Breast Cancer Study Patient Information Brochure (PDF):  This four-column brochure can be printed double-sided (short-edge binding) on 8.5 x 14 legal size paper and folded into a booklet (double parallel fold). A patient-accessible online version of this information is available here.

You can find a more comprehensive list of sites that have the study open, including non-SWOG sites, in the "Contacts and Locations" section of the ClinicalTrials.gov e3 S1207 page.

For questions about the content on this page, please contact communications@swog.org